Bank of America’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
Sell
-1,580
Closed -$929K 7318
2018
Q1
$929K Buy
+1,580
New +$985K ﹤0.01% 4435
2017
Q2
Sell
-2,727
Closed -$2.59M 7165
2017
Q1
$2.59M Buy
2,727
+660
+32% +$615K ﹤0.01% 3644
2016
Q4
$1.66M Buy
+2,067
New +$1.86M ﹤0.01% 3927
2016
Q1
Sell
-793
Closed -$988K 7297
2015
Q4
$988K Sell
793
-946
-54% -$1.56M ﹤0.01% 4379
2015
Q3
$2.35M Sell
1,739
-41
-2% -$67.7K ﹤0.01% 3603
2015
Q2
$3.2M Buy
+1,780
New +$2.76M ﹤0.01% 3008
2014
Q4
Sell
-31
Closed -$12K 7950
2014
Q3
$12K Sell
31
-26
-46% -$12.5K ﹤0.01% 7264
2014
Q2
$35K Buy
57
+7
+14% +$3.9K ﹤0.01% 6886
2014
Q1
$34K Sell
50
-32
-39% -$21.4K ﹤0.01% 6647
2013
Q4
$53K Sell
82
-9
-10% -$5.36K ﹤0.01% 6523
2013
Q3
$54K Buy
91
+53
+139% +$23.9K ﹤0.01% 6382
2013
Q2
$12K Buy
+38
New +$10.6K ﹤0.01% 7127

Other funds holding TCRT

Bank of America's TCRT Position: Q1 2026 in Review

Bank of America sold out of Alaunos Therapeutics (TCRT) in Q1 2026, closing a stake of 89 shares — an estimated $287 sold.

Bank of America first reported a position in TCRT in Q2 2013 and held it in 51 quarters. The position peaked at $6.02M in Q2 2015. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Bank of America reported no remaining Alaunos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 89 Alaunos Therapeutics shares in Q1 2026, an estimated $287.
  • Bank of America first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 51 quarters.
  • Bank of America's Alaunos Therapeutics position peaked at $6.02M in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.